Sarepta’s Elevidys to Remain on Market With New FDA Warning
Sarepta Therapeutics Inc.’s controversial gene therapy for a rare muscle condition will remain available in the US with a strict…
Tag: Elevidys
Sarepta Announces Voluntary Pause of Elevidys Shipments in US
Sarepta Therapeutics Inc. announced that the company plans to temporarily pause all shipments of its gene therapy to treat Duchenne…
Sarepta stock falls on FDA gene therapy Elevidys comment
Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US,…